News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AVI BioPharma And USAMRIID Announce NEUGENE Antisense Drug Demonstrates Efficacy Against Ebola Virus



10/19/2005 5:12:00 PM

AVI BioPharma, Inc. (Nasdaq:AVII), and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) today announced positive results from experiments testing the effect of AVI's NEUGENE(R) antisense drugs against Ebola virus (EBOV) in vivo. The NEUGENE compounds targeted several EBOV genes.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES